MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
7.32
+0.03
+0.41%
After Hours: 7.32 0 0.00% 16:00 04/26 EDT
OPEN
7.34
PREV CLOSE
7.29
HIGH
7.46
LOW
7.12
VOLUME
92.05K
TURNOVER
0
52 WEEK HIGH
9.00
52 WEEK LOW
1.620
MARKET CAP
368.76M
P/E (TTM)
-3.9243
1D
5D
1M
3M
1Y
5Y
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
TScan Therapeutics, Inc. Is a clinical-stage biopharmaceutical company focused on the development of T cell therapies for the treatment of cancer. The underwriters of its previously announced public offering have partially exercised their over-allotment option to purchase additional shares.
Barchart · 3d ago
Tscan Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
Press release · 3d ago
Unveiling 4 Analyst Insights On TScan Therapeutics
TScan Therapeutics underwent analysis by 4 analysts in the last quarter. The company is a biopharmaceutical company focused on the development of cancer treatments. The average price target for TScanTherapeutics is $10.75 and the company's 12-month revenue growth rate is 132.99%. The company has an impressive financial performance.
Benzinga · 3d ago
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Benzinga · 3d ago
TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 27TH ANNUAL MEETING
Reuters · 4d ago
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
Simplify Propel Opportunities ETF (SURI) is a healthcare-based fund that provides exposure to global fixed-income and equity markets in the healthcare sector. The fund offers a near-13% yield from its distributions. SURI has a since-inception return of -13%, but its recent performance has shown potential for growth.
Seeking Alpha · 5d ago
Weekly Report: what happened at TCRX last week (0415-0419)?
Weekly Report · 5d ago
TSCAN THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING
Reuters · 04/19 14:05
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.